TMates Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 7.7/10
Best for: coaching inside the $249/month rather than sold separately
TMates's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
In the price
No insurance needed · Vetted by our editors
TMates is a Miami-based telehealth platform selling compounded semaglutide at $249/mo and compounded tirzepatide at $297/mo across all 50 states plus Puerto Rico. The model is messaging-first, with independent licensed prescribers and third-party compounding pharmacies.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to TMates
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
TMates at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $249/mo (Verbatim ladder: 1 Month $249 / 3 Months $217/mo Save 13% $650 / 6 Months $175/mo Save 30% $1050 / 12 Months $158/mo...)
- Pricing model
- Flat — dose increases don't raise the monthly price
- What's included
- Medication · Consult · Shipping · Coaching
- Availability
- All 50 states
- FDA status
- No FDA warning letter on record
How TMates scores
Six columns, each one computed from something TMates has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
4.2/10$297/month is 11% above the register median of $267 for compounded tirzepatide.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10On the seller's own pages, a price is published before the questionnaire starts.
Trust & Safety15%
7.5/10does not name a dispensing pharmacy; shows a price before asking for health information; publishes its state list. Our verification confidence is medium.
Accessibility10%
10.0/10Publishes coverage in 50 of 50 states.
Support10%
8.5/10The price covers medication, consult, shipping, coaching.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on TMates
Last checked July 2026- Re-read the price on file across 2 dose or plan tiers
- Checked state coverage: all 50
- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: medium.
What signing up with TMates involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1TMates publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3TMates does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- 4The monthly price is recorded as covering medication, consult, shipping, coaching.
- Cheapest standing monthly prices on record: semaglutide $249, tirzepatide $297. Membership fees, first-month rates and insured copays are excluded from those figures.
- Coverage is published for all 50 states.
- The medication is compounded, so it is not an FDA-approved product and has not been reviewed by the agency for safety, effectiveness or manufacturing quality.
GLP-1 medications TMates offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
Verbatim ladder: 1 Month $249 / 3 Months $217/mo Save 13% $650 / 6 Months $175/mo Save 30% $1050 / 12 Months $158/mo Save 37% $1900. Injectable or Oral, same price. Includes medication and ongoing support; free shipping; cancel anytime. UNCHANGED vs providers.json pricing rows; providers.json description field's '$199/mo' is stale.
Verbatim ladder: 1 Month $297 / 3 Months $267/mo Save 10% $800 / 6 Months $217/mo Save 27% $1299 / 12 Months $167/mo Save 44% $1999. Injectable or Oral, same price. UNCHANGED vs providers.json.
Check the price yourself before you pay
Every figure here was read off TMates's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Semaglutide at $249 a month, within the normal band around this register's $189 median for the same drug and form
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- The monthly figure covers medication, consult, shipping, coaching
- Coverage is published for all 50 states
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
What TMates charges
The standing price at TMates is $249/month, unchanged as the dose goes up. That sits above the middle of the market, which puts the burden on whatever else is in the package. Flat dose pricing matters more than it reads: on a tiered plan the bill grows as the dose does, which means the figure that persuaded you to sign up is not the figure you end up living with.
- Compounded semaglutide — $249/month
- Compounded tirzepatide — $297/month
The median standing price across the GLP-1 providers we track is about $169/month, so this is a premium, and a premium has to buy something. Check what is bundled before accepting it.
Breeze Meds dispenses semaglutide and tirzepatide from $199/month, which makes it the honest comparison to run before committing here.
What TMates dispenses
TMates prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two best-evidenced weight-loss molecules currently on the market. These are compounded preparations from a licensed pharmacy rather than approved pens, which is where the lower price comes from. A compounded drug is not FDA-approved as a finished product — the specific preparation has not been reviewed for safety, efficacy or manufacturing quality.
What we could verify
On the record: it treats patients in all 50 states and coaching is included rather than sold on top. We searched the federal warning-letter record for this operator and came back with nothing. Because the medication is compounded and no dispensing pharmacy is named publicly, the single most useful question to ask at intake is which licensed pharmacy fills the prescription. A seller that will not answer that has told you something. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You are optimizing for the twelve-month total rather than the first bill — a flat-rate seller such as CoreAge Rx will usually win that arithmetic.
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to bill insurance. Like most of this market, this is cash-pay.
It fits if
- you want the price to stop moving as your dose climbs
- you want coaching bundled rather than metered
- you need access regardless of where you live
Our read
TMates costs more than the middle of this market. If the extras it charges for are ones you would actually use, that is a defensible trade. If not, the same molecule is available for less. Direct Meds is the nearest comparison we track, and worth reading alongside this.
The Bottom Line
TMates's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Before you pay TMates
Starting at $249/month. Check today's price, then book the free consultation.
Where TMates is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this TMates review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See TMates's current pricing
Plans start at $249/month. The free consultation is where you learn whether you qualify, and what it costs today.